Skip to main content
Fig. 5 | BMC Infectious Diseases

Fig. 5

From: Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults

Fig. 5

Solicited injection-site adverse events after the first (a) and second (b) dose, and general adverse events after the first (c) and second dose (d) in infants aged 6–35 months in the total vaccinated cohort. IIV4-I, quadrivalent inactivated influenza vaccine manufacturing by investigational process; IIV4, licenced quadrivalent inactivated influenza vaccine; CI, confidence interval; N, number of subjects in the total vaccinated cohort who returned diary cards

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us